Abstract
Oncogenic mutations in the KRAS gene are found in 30–50% of colorectal cancers (CRC), and recent findings have demonstrated independent and nonredundant roles for wild-type and mutant KRAS alleles in governing signaling and metabolism. Here, we quantify proteomic changes manifested by KRAS mutation and KRAS allele loss in isogenic cell lines. We show that the expression of KRASG13D upregulates aspartate metabolizing proteins including PCK1, PCK2, ASNS, and ASS1. Furthermore, differential expression analyses of transcript-level data from CRC tumors identified the upregulation of urea cycle enzymes in CRC. We find that expression of ASS1 supports colorectal cancer cell proliferation and promotes tumor formation in vitro. We show that loss of ASS1 can be rescued with high levels of several metabolites.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6683-6699 |
| Number of pages | 17 |
| Journal | FEBS Journal |
| Volume | 288 |
| Issue number | 23 |
| DOIs | |
| State | Published - Dec 2021 |
Funding
This research was carried out with support from the National Resource for Translational and Developmental Proteomics under Grant P41 GM108569 from the National Institute of General Medical Sciences (NLK) and supported by the Sherman Fairchild Foundation. PFD acknowledges a NSF Fellowship under award number 2015210477, and the authors thank Emily Bojas and Henry Rodriguez for support in accessing proteomic data and isogenic cell lines from the National Cancer Institute (Office of Cancer Clinical Proteomics Research), National Institutes of Health, under Contract No. HHSN261200800001E.
Keywords
- aspartate
- colorectal cancer
- metabolomics
- mutant KRAS
- quantitative proteomics
- urea cycle
ASJC Scopus subject areas
- Molecular Biology
- Biochemistry
- Cell Biology
